AspyreRx Launch Target healthcare providers and payers supporting diabetes management to expand AspyreRx adoption, leveraging recent U.S. launch and integration with Glooko to drive prescriptions, patient onboarding, and data tracking.

Strategic Partnerships Leverage partnerships with the American College of Lifestyle Medicine and Federally Qualified Health Centers to broaden access, scale distribution, and create referral pathways for digital behavioral therapies among diverse patient populations.

Breakthrough Designation Position the FDA Breakthrough Device designation for MASH/NASH as a differentiator to engage cardiometabolic care teams, gastroenterology, and hepatology stakeholders seeking innovative, regulated digital therapies.

Clinical Evidence Emphasize top-line data showing AspyreRx boosts outcomes with GLP-1 therapies to potential partners in chronic disease management, endocrinology, and primary care networks seeking enhanced treatment adherence.

Market Expansion Explore opportunities with payers and health systems in cardiometabolic disease management, offering a scalable digital therapeutic platform that aligns with cost-effective care goals and can integrate into existing telehealth and EHR workflows.